STOK
Stoke Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -25.0% ·
share flow +18.5% ·
net new positions -20.0%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 80 | -1 | 41.15M | $1.35B | +7 | −7 |
| Q1 2026 | 83 | +2 | 38.21M | $1.24B | +9 | −7 |
| Q4 2025 | 80 | -1 | 35.34M | $1.12B | +1 | −2 |
| Q3 2025 | 16 | +1 | 26.41M | $620.57M | +1 | — |
| Q2 2025 | 12 | 0 | 21.43M | $243.28M | +1 | −1 |
| Q1 2025 | 9 | -3 | 5.10M | $33.93M | — | −3 |
| Q4 2024 | 12 | +1 | 4.31M | $47.51M | +2 | −1 |
| Q3 2024 | 10 | +2 | 3.11M | $38.25M | +3 | −1 |
| Q2 2024 | 8 | — | 2.69M | $36.29M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Marshall Wace ✦ | 2.13M | +124.1% | $14.18M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 2 | Marshall Wace ✦ | 2.13M | +124.1% | $14.18M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | State Street Global Advisors ✦ (passive) | 1.58M | -0.8% | $10.48M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 901.99K | +2.8% | $6.00M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 901.99K | +2.8% | $6.00M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 178.30K | +38.2% | $1.19M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Wellington Management ✦ | 135.96K | +0.8% | $904,134 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | Wellington Management ✦ | 135.96K | +0.8% | $904,134 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 107.56K | +16.2% | $715,287 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 107.56K | +16.2% | $715,287 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 39.10K | +4.4% | $261,000 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 12 | Millennium Management ✦ | 19.62K | -74.5% | $130,473 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 12.85K | -45.6% | $85,433 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 12.85K | -45.6% | $85,433 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 12.85K | -45.6% | $85,433 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 12.85K | -45.6% | $85,433 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 12.85K | -45.6% | $85,433 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Norges Bank | $3.47M | was 0.0% |
| Two Sigma Investments | $595,068 | was 0.0% |
| D. E. Shaw & Co. | $309,314 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 196 holders, 69.25M shares, $2.18B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.72K sh · $86,932
Officer · 145 sh · $4,708
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology